Hims & Hers Health, Inc. (HIMS) AI Stock Analysis

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers directly with licensed healthcare professionals through its websites and mobile application. The company provides consultations and personalized treatments focused on sexual health and wellness, skincare, hair care, and overall wellness. Its offerings include prescription medications alongside non-prescription products, such as over-the-counter drugs, devices, cosmetics, and dietary supplements including vitamin C, melatonin, biotin, and collagen protein. Its skincare line includes moisturizers, serums, and cleansers, while sexual health products include condoms, lubricants, vibrators, and climax delay sprays. Hims & Hers distributes products through direct-to-consumer sales and wholesale channels.

Annual revenue grew from $271.9M in FY2021 to $2.35B in FY2025, representing a 5-year revenue CAGR of 73.6%. Gross margin reached 73.8% in FY2025, compared to 79.5% in FY2024 and 82.0% in FY2023. Operating margin was 4.5% in FY2025, producing net income of $128.4M and EPS of $1.07. Over the trailing twelve months, revenue reached $2.58B, while net margin fell to -5.5% and EPS dropped to -$0.64. For the latest quarter ended June 30, 2026, quarterly revenue increased 38.2% year-over-year, while quarterly earnings declined 17.4%.

As of June 30, 2026, Hims & Hers held $841.0M in cash and short-term investments against total debt of $1.55B, resulting in net debt of $705.2M. The company recorded a current ratio of 0.93 and a debt-to-equity ratio of 4.77, supported by $324.1M in shareholders' equity. Operating cash flow reached $300.0M in FY2025. During that year, the company spent $226.0M on capital expenditures, resulting in free cash flow of $74.0M, while dedicating $90.0M to share buybacks.

Hims & Hers trades at a forward P/E of 73.5x, compared to the 17.3x median of its US-listed Healthcare peers. Its EV to EBITDA ratio is 205.9x versus the peer median of 12.0x, while its price-to-sales ratio stands at 2.5x, below the peer median of 4.1x. Over the past year, the stock declined 52.5%, lagging the S&P 500 return of 16.8%. Over a 5-year period, the stock returned 235.8% compared to 83.0% for the S&P 500.

Wall Street analysts hold 1 Strong Buy, 2 Buy, and 12 Hold ratings on HIMS. The mean price target of $31.15 is 11.0% above the last close of $28.07. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.56 on revenue of $3.21B. For the following fiscal year, 11 analysts project EPS of $0.42 on revenue of $4.00B. The company beat EPS expectations in 2 of the past 4 quarters, with next earnings scheduled for November 9, 2026.

This page is an AI-written research summary of Hims & Hers Health, Inc. (HIMS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HIMS income statement, HIMS balance sheet, HIMS key metrics, HIMS analyst forecast, HIMS chart. See the HIMS stock overview for the latest quote and news.